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Purpose: Although the risk of oxaliplatin-induced neuropathy depends on cumulative 
oxaliplatin dose, susceptibility to this adverse event differs greatly among patients.  In 
this study, we investigated the associations between oxaliplatin-induced neuropathy and 
the following polymorphisms: glutathione S-transferase  (GSTP1) Ile105Val, and 
glyoxylate aminotransferase (AGXT) Pro
11
Leu and AGXT Ile
340
Met. 
Experimental Design: Eighty-two Japanese patients with histologically confirmed 
colorectal cancer who received at least six cycles of the modified FOLFOX6 
(m-FOLFOX6) regimen were enrolled.  To minimize differences in cumulative 
oxaliplatin dose between patients, oxaliplatin-induced neuropathy was evaluated using an 
oxaliplatin-specific scale during the two-week period after completion of the sixth cycle 
of treatment.   
Results: Forty-four patients developed grade 2/3 oxaliplatin-induced neuropathy.  There 
were more patients carrying at least one GSTP1 
105
Val allele among the group with grade 
2/3 neuropathy (18/44, 41%) than among the group with grade 1 neuropathy (9/38, 24%), 
although the difference was not statistically significant (P = 0.098).  There were similar 
numbers of patients carrying at least one AGXT 
105
Met allele in the grade 2/3 neuropathy 
(7/44, 16%) and grade 1 neuropathy groups (5/38, 13%; P = 0.725).  The AGXT 
11
Leu 
allele was not found in any of our patients or controls.   
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Conclusions: We found no significant association between oxaliplatin-induced 
neuropathy and the GSTP1 Ile
105
Val and AGXT Ile
340
Met polymorphisms.  Given that no 
AGXT 
11
Leu allele was found among our study population (n = 177), evaluating this 




Oxaliplatin, a third-generation diaminocyclohexane platinum compound, is a key drug in 
the chemotherapeutic treatment of patients with advanced colorectal cancer (1-3).   
Oxaliplatin is widely used in palliative settings, and in recent times its efficacy in 
neoadjuvant and adjuvant settings has also been established, thus an increasing number of 
colorectal cancer patients are receiving this drug (4, 5).  Oxaliplatin often causes 
neuropathy, which limits the ongoing use of this drug in spite of its wide range of efficacy.  
The risk of developing oxaliplatin-induced neuropathy depends on cumulative oxaliplatin 
dose (2, 6, 7).  However, susceptibility to oxaliplatin-induced neuropathy differs greatly 
among patients.  Some patients suffer from persistent neuropathy for more than 2 years 
after withdrawal of oxaliplatin, whereas others can tolerate a cumulative oxaliplatin dose 
of more than 800 mg/m
2
 without experiencing neuropathy (6-9).  Since there is currently 
no effective treatment for oxaliplatin-induced neuropathy, risk assessments for this 
adverse event using a pharmacogenetic approach are clinically valuable.    
To date, several genes have been identified as being of interest in the context of the 
efficacy and toxicity of oxaliplatin.  Glutathione S-transferase  (GSTP1) is a 
xenobiotic-metabolizing
 
enzyme involved in the detoxification of a variety of 
chemotherapeutic
 
drugs, including platinum derivatives (10).  Rs1695, a 
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non-synonymous single nucleotide polymorphism (SNP) of GSTP1, converts Ile to Val at 
codon 105 and reportedly alters the enzymatic activity of the molecule (10-13).  Given 
that altered GSTP1 enzyme activity is likely to affect the detoxification of platinum drugs, 
the association between the GSTP1 Ile
105
Val polymorphism and clinical response to 
platinum-based chemotherapy has been examined (14-28).  However, few of these 
studies were designed to evaluate oxaliplatin-induced neuropathy as a primary endpoint.  
In one such study, that by Lecomte et al., it was found that grade 3 neuropathy was 
significantly more frequent among patients harboring the homozygous GSTP1 
105
Ile 
allele than among patients with other genotypes.  These authors hypothesized that the 
GSTP1 
105
Ile protein weakens the cell’s defenses against oxaliplatin neurotoxicity via 
inhibition of c-Jun NH2-terminal kinase activity (17).   The results of several other studies 
support this hypothesis (25, 27), whereas other groups have reported no significant 
association between this genotype and oxaliplatin neurotoxicity (24, 26) or have obtained 
contradictory results (21, 28).  Other experimental findings that indirectly challenge the 
view of Lecomte et al. are that the GSTP1 
105
Val protein is a less potent detoxifier of 
carcinogens than the GSTP 1 
105
Ile protein (13) and that patients with the Val/Val 
genotype have been found to receive significant survival benefit from oxaliplatin (14).  
Thus, the role of the GSTP1 Ile
105
Val polymorphism in predicting oxaliplatin-induced 
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neuropathy is still controversial.   
Oxaliplatin affects neural voltage-gated sodium channels indirectly via one of its 
metabolites, oxalate (29, 30).  Based on the fact that glyoxylate aminotransferase 
(AGXT) is involved in the oxalate metabolic pathway (31), Gamelin et al. hypothesized 
that alterations in AGXT genotype and therefore enzyme activity due to AGXT genotype 
could theoretically affect the likelihood of oxaliplatin-induced neuropathy.  In fact, they 




Met minor polymorphisms are significantly 
associated with a higher risk of oxaliplatin-induced neuropathy (24). 
However, all the above-mentioned studies were carried out using Caucasian patient 
populations, and to date there have been no such studies performed for Asian patients.  
There exist considerable interethnic differences in genotype frequency, which can greatly 
affect the results of pharmacogenetic analyses.  For example, the UGT1A1*28 marker is 
known to vary markedly between ethnic groups (32-34).     







Leu and AGXT Ile
340
Met polymorphisms and the development
 
of 
oxaliplatin-induced neuropathy in Japanese colorectal cancer patients.  To minimize 
differences in cumulative oxaliplatin dose, we studied oxaliplatin-induced neuropathy 
that developed in the 2 weeks after completion of the sixth cycle of m-FOLFOX6.   
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Patients and Methods 
Patients 
Between October 2005 and December 2008, a total of 174 patients with
 
histologically 
confirmed colorectal cancer received at least six cycles of the m-FOLFOX6
 
regimen at 
two medical centers.  Eighty-two patients (the patients’ characteristics are summarized in 
Table 1) were enrolled in this cohort study.  The remaining patients were excluded 
because they died (n = 60), were referred to another hospital (n = 10), or were lost to 
follow-up (n = 22) before we could obtain informed consent or a blood sample.  The local 
ethics committees of both centers approved the study protocol.  All patients enrolled
 
in 
this study provided written informed consent.  Patient registration and data management 
were conducted at a data center at Kyoto University Hospital (Translational Research 
Center).  Forty-eight of the 82 patients were chemo-naïve and the others had previously 
undergone at least one chemotherapy regimen other than oxaliplatin-based chemotherapy 
before m-FOLFOX6 (see Table 1 for details).  None of the patients had a history of 
diabetic neuropathy, but two patients had a history of spondylosis.  The m-FOLFOX6 
regimen consists of 85 mg/m
2
 oxaliplatin plus a 400 mg/m
2
 bolus of 5-fluorouracil and 
200 mg/m
2
 L-leucovorin on day 1, and thereafter a 46-h infusion of 2400 mg/m
2
 
5-fluorouracil every 2 weeks (35).  The dose and schedule for m-FOLFOX6 were 
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adjusted at the discretion of individual physicians according to baseline bone marrow 
function or the occurrence of adverse events during the previous cycle.  Bevacizumab 
was concomitantly administered to two patients.  Blood tests and physical examinations, 
including evaluation of oxaliplatin-induced neuropathy, were performed before each 
cycle.  Instances of oxaliplatin-induced neuropathy that occurred during the two weeks 
after completion of the sixth cycle of m-FOLFOX6 were graded using an 
oxaliplatin-specific scale
 
(grade 1: paresthesia, dysesthesia of short duration; grade
 
2: 
paresthesia, dysesthesia persisting between cycles; grade
 
3: paresthesia, dysesthesia 
causing functional impairment) (6, 36).  In this study, we classified patients without 
paresthesia or dysesthesia into the grade 1 group. 
 DNA extraction and genotyping 
Genomic DNA was extracted from whole blood using the phenol-chloroform extraction 






Leu and AGXT 
Ile
340
Met genotypes were determined by using a fluorescence quenching probe (QProbe, 
Bex Co., Ltd., Tokyo, Japan) (37, 38).  Briefly, a QProbe contains cytosine at its 5’ or 3’ 
end, which is labeled with a fluorophore that is quenched by guanine.  When a QProbe 
hybridizes with the target DNA, its fluorescence is quenched by the guanine in the target 
that is complementary to the modified cytosine.  By monitoring fluorescence intensity, 
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each genotype can be determined.  The frequencies of the three SNPs in the general 
Japanese population were also examined using DNA samples from healthy Japanese 
volunteers in Pharma SNP Consortium (Tokyo, Japan) (39).  This population is referred 
to hereafter as the control Japanese population.  The investigators performing the genetic 
analysis were blinded to the patients’ characteristics and clinical condition.  The 
characteristics and frequencies of the studied polymorphisms are shown in Table 2.   
Statistical analysis  
The primary endpoint of the study was the association between genotype distribution and 
the occurrence of grade 2/3 oxaliplatin-induced neuropathy during the 2 weeks after 
completion of the sixth cycle of m-FOLFOX6 treatment.  The planned sample size (n=82) 
was specified in the protocol to provide 80% power to detect an odds ratio (OR) of 5.4. 
The calculations were based on a previous finding that the OR of developing grade 3 
oxaliplatin-induced neuropathy in a patient without the GSTP1 
105
Val allele was 5.54 (17).  
We estimated that the frequency of patients in our Japanese population with at least one 
GSTP1 
105
Val allele was 21% and used estimated incidences of grade 2/3 
oxaliplatin-induced neuropathy after the first six cycles of mFOLFOX6 for patients with 
and without a GSTP1 
105
Val allele of 30% and 70%, respectively.  Statistical analysis was 
performed using a two-sided 2/Fisher’s exact test with a significance level of 5%, and 
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quantified by calculating ORs with 95% confidence intervals (95% CI).  All statistical 




Patient characteristics are summarized in Table 1.  The median cumulative dose of 
oxaliplatin was 510 mg/m
2
 (range, 336-510 mg/m
2
).  Although some patients received a 
lower cumulative dose than expected, the most common cause of dose adjustment was 
neutropenia and none of our patients underwent a dose reduction because of neurotoxicity.  
Forty-four patients (54%) developed grade 2/3 oxaliplatin-induced neuropathy (as scored 
using the oxaliplatin-specific scale) during the 2 weeks after completion of the sixth cycle 
of m-FOLFOX6.  No significant differences in age, gender or cumulative oxaliplatin dose 
were observed between the group of patients with grade 2/3 neuropathy and those with 
grade 1 neuropathy (Table 3).    
We performed genotyping analysis for the rs1695, rs34116584 and rs4426527 SNPs, 




Leu and AGXT 
Ile
340
Met polymorphisms. We performed this analysis for 44 patients with grade 2/3 
neuropathy (group A) and 38 patients with grade 1 neuropathy (group B).  The 
frequencies of the variant allele in rs1695 (G), corresponding to GSTP1
105
Val, were 0.216 
for group A and 0.132 for group B.  Although the frequency was higher in group A, the 
difference was not statistically significant (P = 0.158) (Table 2).  The frequency of allele 
G in the control Japanese population was 0.147, which is similar to that of group B.  
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When a dominant model for the variant allele (G) was applied for comparison, the 
number of patients carrying at least one variant allele was higher in group A (18/44, 41%) 
than in group B (9/38, 24%) although the difference was not statistically significant (P = 
0.098) (Table 2).  A similar trend was observed when the same comparison between 
group A and the control Japanese population was performed (P = 0.080) (Table 2). 
The G allele of SNP rs4426527, corresponding to AGXT Ile
340
Met, was present at 
frequencies that were not significantly different in group A and group B (P = 0.553) 




was absent in 
group A, group B and the control Japanese population (n = 177, data not shown).  The 
frequencies of GSTP1 Ile
105
Val and AGXT Ile
340





In this study, to minimize differences in cumulative oxaliplatin dose among patients, we 
attempted to evaluate oxaliplatin-induced neuropathy during the two weeks after 
completion of the sixth cycle of m-FOLFOX6.  As a result, we evaluated early-onset 
neuropathy rather than the most severe grade of neuropathy that is associated with 
oxaliplatin.    
Lecomte et al. reported that grade 3 oxaliplatin-induced neuropathy, as scored using the 
oxaliplatin-specific scale, was significantly more frequent among patients harboring the 
homozygous GSTP1 
105
Ile allele (17).  Our planned sample size of 82 was based on these 
findings.  In contrast to the findings of Lecomte et al., we found that grade 2/3 neuropathy 
was more common among patients harboring at least one GSTP1
105
Val allele, although 
the difference was not statistically significant (OR, 2.23; 95% CI, 0.86-5.82; P = 0.098; 
Table 2).  There are several possible reasons for this discrepancy between the outcomes of 
two studies.  As mentioned above, our findings reflect our focus on early-onset 
neuropathy, while Lecomte et al. studied the most severe grade of neuropathy 
experienced during oxaliplatin treatment.  Our findings are in line with those of Grothey 
et al., who determined that patients harboring at least one GSTP1
105
Val allele were more 
likely to experience early-onset oxaliplatin-induced grade 2/3 neuropathy (28).  Because 
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Grothey et al. studied neuropathy that developed before the cumulative oxaliplatin dose 
reached 600 mg/m
2
, their approach is more similar to ours than that of Lecomte et al.  
Since functional impairment due to oxaliplatin neuropathy does not necessarily develop 
in a progressive manner but develops suddenly in some patients (40), it is possible that 
those who are prone to developing early-onset neuropathy have different genotypes from 
those who suffer from functional impairment due to oxaliplatin neuropathy.   
Genetic differences related to ethnic background may also be a reason for the differences 
between the present results for Japanese patients and the previous results for Caucasian 
patients.  In particular, because of the very low frequency of the GSTP1 105 Val/Val 
genotype among our patients as well as the control Japanese population, we cannot 
accurately assess the role of this genotype in predicting the likelihood of 
oxaliplatin-induced neuropathy.  Previously published data on the GSTP1 Ile
105
Val 
polymorphism and oxaliplatin neurotoxicity are summarized in Table 4.   
There has been only one prior study in which the associations between AGXT genotypes 
and oxaliplatin-induced neuropathy have been investigated (24).  In contrast to the 
findings of Gamelin et al., we did not see any significant association between 
oxaliplatin-induced neuropathy and the AGXT Ile
340
Met polymorphism.  This might also 





Leu allele in our study, whereas 30% of patients were found to harbor at least one 
AGXT 
11
Leu allele in a Caucasian patient population (24).  In contrast to other clinical 
responses, such as tumor shrinkage or neutropenia, oxaliplatin-induced neuropathy is 
minimally affected by concomitantly administered drugs or genetic changes in the tumor 
cell, so genetic polymorphisms are particularly relevant in the context of susceptibility to 
oxaliplatin-induced neuropathy.  In future pharmacogenetic studies, in order to obtain the 
most consistent results, we recommend that early-onset neuropathy be evaluated 
separately from the most severe neuropathy and inter-patient differences in cumulative 
oxaliplatin dose be minimized.   
In summary, we found no significant associations between oxaliplatin-induced 
neuropathy during the 2-week period after the completion of six cycles of m-FOLFOX6 
and the GSTP1 Ile
105
Val and AGXT Ile
340
Met polymorphisms in Japanese colorectal 
cancer patients.  Since no patients harbored the AGXT 
11
Leu allele in the present study, it 
seems likely that evaluating this polymorphism in Japanese patients in future studies will 
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Moderately differentiated 58 (71)
Poorly differentiated 1 (1)
Other 12 (15)















Table 1.  Patient characteristics (n = 82)
* Several patients received more than one regimen
 
Table1
Table 2. Genotype and allele frequencies for the investigated polymorphisms       
             
Polymorphism rs ID 
Nucleotide Amino acid 
Sample set 
Genotype distributions (%) 
Freq. A2 P-valuea 
 
ref. (A1) var. (A2) ref. var. A1/A1 A1/A2 A2/A2  
GSTP1  Ile105Val rs 1695 A G Ile Val Grade 2/3 26 (59.1) 17 (38.6) 1 (2.3) 0.216   
      Grade 1 29 (76.3) 8 (21.0) 1 (2.6) 0.132 0.158 
 
      Controlb 68 (73.9) 21 (22.8) 3 (3.2) 0.147 0.155 
 
             
            
 
             
AGXT  Ile340Met rs 4426527 A G Ile Met Grade 2/3 37 (84.1) 6 (13.7) 1 (2.3) 0.091   
      Grade 1 33 (86.8) 5 (13.2) 0 0.066 0.553 
 
            Controlb 82 (91.1) 8 (8.9) 0 0.044 0.132 
 
aP-values are calculated for grade 2/3 vs. grade 1 or grade 2/3 vs. control.       
ba sample set representing a control population of healthy Japanese subjects was used. 












A1/A1 A1/A2+A2/A2  
 Grade 2/3 26 18     
GSTP1  Ile105Val Grade 1 29 9  0.098 2.23 (0.86 – 5.82) 14, 16 
 Controlb 68 24  0.080 1.96 (0.92 – 4.20)  
        
        
        
AGXT  Ile340Met Grade 2/3 37 7     
 Grade 1 33 5  0.725 1.25 (0.36 – 4.31) 23 





























Table 3. Association between clinical variables and genotypes and
oxaliplatin-induced neuropathy
n (% )
Grade 2 Grade 3Grade 1
9 (38) 0 (0)15 (62)






18 (49) 1 (3)
8 (32)
34 (59) 1 (2)
18 (49)
20 (44)
26 (47) 0 (0)
19 (61) 1 (3)
29 (52)
23 (40)
25 (56) 0 (0)
0 (0)
1 (100) 0 (0)
36 (51) 1 (1)
1 (50) 0 (0)
6 (55)
16 (64) 1 (4)
1 (50)
Table3
Table 4. Findings from published studies on GSTP1 Ile105Val and oxaliplatin-induced neuropathy among patients with colorectal cancer   
Study Year Sample size Ethnicity  Regimen  








A1/A1 A1/A2 A2/A2 
Lecomete et al.17 2005 64 Caucasian* Mainly FOLFOX4 (72%) ≥500 39 (61) 20 (31) 5 (8) A1/A1 0.02 
Grothey et al.28 2005 288 Caucasian  FOLFOX4 ≤600 120 (42) 130 (45) 38 (13) A1/A2 + A2/A2 0.03 
Ruzzo et al.21 2007 166 Caucasian  FOLFOX4 N/A 92 (55) 62 (37) 12 (8) A2/A2 < 0.001 
Gamelin et al.24 2007 122 Caucasian  FOLFOX4 255–2125  54 (44) 56 (46) 12 (10) ns ns 
Pare et al.25 2008 126 Caucasian  FOLFOX4 ≥510 44 (35) 49 (49) 20 (16) A1/A1 0.08 
Kweekel et al.26 2009 56 Caucasian  XELOX ≥500 25 (45) 25 (45) 6 (11) ns ns 
Current study 2009 82 Japanese  m-FOLFOX6 ≤510 55 (67) 25 (30) 2 (2) A1/A2 + A2/A2 0.1 
*Except four African patients and one Asian patient;  N/A, not applicable;  ns, not significant;  XELOX regimen consists of 130 mg/m2 oxaliplatin plus 1000 mg/m2 capecitabine b.i.d every 3 
weeks. 
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